Clinical Trial Update: Efficacy and Safety of BG2109 in Chinese Subjects With Endometriosis [Phase 3]

View source ↗

Summary

Phase 3 trial update on BG2109 in Chinese patients with endometriosis, focusing on efficacy and safety for moderate to severe endometriosis-associated pain.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometriosis

Drugs mentioned

• BG2109

Snippet

Sponsor: Bio Genuine (Shanghai) Biotech Co., Ltd. | Conditions: Endometriosis, Moderate to Severe Endometriosis-associated Pain | Phase 3 | Status: UNKNOWN